Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL OLE long-term infigratinib study in children with achondroplasia
2024-513857-55-00Phase 2Authorised
- Sponsor
- QED Therapeutics
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of infigratinib in achondroplasia (ACH) (2 arms), sponsored by QED Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events and serious treatment-emergent adverse events and Change over time in height Z-score. Planned start Feb 2022; status: authorised.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2024-513857-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513857-55-00.